Analyzing Genes That May Increase the Risk of Developing High Blood Pressure

November 26, 2013 updated by: Case Western Reserve University

Fine Mapping of Hypertension Genes Detected by Admixture Mapping in the FBPP

High blood pressure is one of the most common health problems in the United States. Genetic variations may cause some people to be more susceptible to developing high blood pressure. This study will identify variations in genes known to play a part in the development of high blood pressure.

Study Overview

Status

Completed

Conditions

Detailed Description

High blood pressure affects nearly one third of all individuals in the United States. It is especially common in African Americans, with more than 40% of African Americans diagnosed with this condition. High blood pressure usually develops earlier in life and is more severe in African Americans than in other racial or ethnic groups. Many factors can cause high blood pressure, including stress, diet, diabetes, kidney disease, or obesity. Previous studies have also shown that genetic variations on two regions of chromosomes 6 and 21 may predispose some people to develop high blood pressure. Admixture mapping is a type of genetic analysis that aims to identify disease-causing genetic variations across different populations of people. Using admixture mapping, this study will examine previously collected genetic samples from African American participants in the Family Blood Pressure Program (FBPP) study and from African American, Mexican American, Nigerian, and Jamaican participants enrolled in other clinical studies. Study researchers will analyze the samples to identify and characterize genetic variations that are associated with an increased risk of high blood pressure in the African American population, as well as other racial and ethnic groups.

Study Type

Observational

Enrollment (Actual)

8687

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Ohio
      • Cleveland, Ohio, United States, 44106
        • Case Western Reserve University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Previously collected genetic samples from African American participants in the Family Blood Pressure Program (FBPP) study and from African American, Mexican American, Nigerian, and Jamaican participants enrolled in other clinical studies will be examined.

Description

Inclusion Criteria:

  • Participated in the FBPP study (African American [800 people with high blood pressure and 800 control group participants] and Mexican American participants)
  • Participated in the American Family Study (African American participants)
  • Participated in the Phenotyping Study (African American, Nigerian, and Jamaican participants)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Genetic variations
Time Frame: Measured through admixture mapping genetic analysis
Measured through admixture mapping genetic analysis

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Case Western Reserve University

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

  • Principal Investigator: Xiaofeng Zhu, PhD, Case Western Reserve University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2007

Primary Completion

December 7, 2022

Study Completion (Actual)

June 1, 2012

Study Registration Dates

First Submitted

October 24, 2007

First Submitted That Met QC Criteria

October 24, 2007

First Posted (Estimate)

October 26, 2007

Study Record Updates

Last Update Posted (Estimate)

November 27, 2013

Last Update Submitted That Met QC Criteria

November 26, 2013

Last Verified

April 1, 2009

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1415
  • R01HL086718 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe